NASDAQ:PRTA Prothena (PRTA) Stock Price, News & Analysis → Elon Musk Secret Crypto Plot Exposed (From Crypto 101 Media) (Ad) Free PRTA Stock Alerts $23.54 -0.20 (-0.84%) (As of 05:14 PM ET) Add Compare Share Share Today's Range$23.29▼$24.2050-Day Range$20.34▼$30.3052-Week Range$19.65▼$79.38Volume559,154 shsAverage Volume735,436 shsMarket Capitalization$1.26 billionP/E RatioN/ADividend YieldN/APrice Target$68.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Prothena alerts: Email Address Prothena MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside184.5% Upside$68.14 Price TargetShort InterestBearish12.34% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.88) to ($4.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.22 out of 5 starsMedical Sector511th out of 903 stocksPharmaceutical Preparations Industry235th out of 420 stocks 4.4 Analyst's Opinion Consensus RatingProthena has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageProthena has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.34% of the outstanding shares of Prothena have been sold short.Short Interest Ratio / Days to CoverProthena has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Prothena has recently increased by 2.47%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldProthena does not currently pay a dividend.Dividend GrowthProthena does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTA. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Prothena this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for PRTA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Prothena to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prothena insiders have not sold or bought any company stock.Percentage Held by Insiders28.10% of the stock of Prothena is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Prothena are expected to grow in the coming year, from ($4.88) to ($4.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prothena is -8.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prothena is -8.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProthena has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Prothena Stock (NASDAQ:PRTA)Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Read More PRTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTA Stock News HeadlinesMay 7, 2024 | markets.businessinsider.comProthena is about to announce its earnings — here's what to expectMay 1, 2024 | stockhouse.comProthena to Report First Quarter 2024 Financial Results on May 8May 7, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 26, 2024 | nasdaq.comCommit To Buy Prothena Corp At $15, Earn 21.3% Using OptionsApril 17, 2024 | investing.comProthena reports potential AL amyloidosis treatmentApril 15, 2024 | businesswire.comProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & LymphomaMarch 13, 2024 | markets.businessinsider.comDemystifying Prothena Corp: Insights From 8 Analyst ReviewsMarch 7, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)May 7, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 5, 2024 | businesswire.comProthena to Participate in Upcoming Healthcare ConferencesMarch 4, 2024 | finance.yahoo.comProthena Appoints David Ford to Newly Created Chief People Officer PositionMarch 1, 2024 | finance.yahoo.comProthena Corporation plc (PRTA)February 23, 2024 | seekingalpha.comProthena: Alzheimer's Data Update In 2024 Could Move The NeedleFebruary 21, 2024 | msn.comProthena appoints Daniel G. Welch as Chair DesignateFebruary 21, 2024 | businesswire.comProthena Announces Appointment of Daniel G. Welch as Director and Chair DesignateFebruary 17, 2024 | finance.yahoo.comPRTA Mar 2024 105.000 callFebruary 17, 2024 | finance.yahoo.comProthena Full Year 2023 Earnings: Beats ExpectationsFebruary 16, 2024 | markets.businessinsider.comPromising Outlook for Prothena’s Amyloidosis Treatments: Analyst Endorses Buy RatingFebruary 16, 2024 | finance.yahoo.comProthena (PRTA) Q4 Earnings Miss Estimates on Higher R&D ExpenseFebruary 16, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Prothena (PRTA)February 16, 2024 | markets.businessinsider.comDecoding 6 Analyst Evaluations For Prothena CorpFebruary 16, 2024 | finance.yahoo.comProthena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call TranscriptFebruary 15, 2024 | finance.yahoo.comProthena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business HighlightsFebruary 15, 2024 | finance.yahoo.comProthena Corp PLC (PRTA) Reports 2023 Financial Results and Provides 2024 OutlookFebruary 15, 2024 | seekingalpha.comProthena Corporation plc 2023 Q4 - Results - Earnings Call PresentationFebruary 15, 2024 | businesswire.comProthena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business HighlightsFebruary 14, 2024 | benzinga.comEarnings Outlook For Prothena CorpSee More Headlines Receive PRTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today5/07/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRTA CUSIPN/A CIK1559053 Webwww.prothena.com Phone(531) 236-2500Fax353-1902-3510Employees173Year FoundedN/APrice Target and Rating Average Stock Price Target$68.14 High Stock Price Target$90.00 Low Stock Price Target$35.00 Potential Upside/Downside+183.1%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-147,030,000.00 Net Margins-160.91% Pretax Margin-175.64% Return on Equity-24.84% Return on Assets-20.24% Debt Debt-to-Equity RatioN/A Current Ratio11.24 Quick Ratio11.24 Sales & Book Value Annual Sales$91.37 million Price / Sales14.15 Cash FlowN/A Price / Cash FlowN/A Book Value$10.46 per share Price / Book2.30Miscellaneous Outstanding Shares53,720,000Free Float38,625,000Market Cap$1.29 billion OptionableOptionable Beta0.30 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Gene G. Kinney Ph.D. (Age 55)President, CEO & Director Comp: $1MMr. Tran B. Nguyen M.B.A. (Age 50)CFO & Chief Strategy Officer Comp: $830.14kMr. Brandon S. Smith (Age 49)Chief Operating Officer Comp: $757.79kMs. Carol D. Karp (Age 71)Chief Regulatory Officer Comp: $701.48kDr. Hideki Garren M.D. (Age 59)Ph.D., Chief Medical Officer Comp: $808.71kMs. Karin L. Walker CPA (Age 61)Chief Accounting Officer & Controller Dr. Wagner M. Zago (Age 51)Chief Scientific Officer Comp: $478.79kMr. Mark C. Johnson C.F.A.Vice President of Investor RelationsMr. Michael J. Malecek (Age 58)Chief Legal Officer Comp: $588.25kMr. David A. Ford (Age 54)Chief People Officer More ExecutivesKey CompetitorsAbCellera BiologicsNASDAQ:ABCLMannKindNASDAQ:MNKDMirum PharmaceuticalsNASDAQ:MIRMBelite BioNASDAQ:BLTESpyre TherapeuticsNASDAQ:SYREView All CompetitorsInsiders & InstitutionsSG Americas Securities LLCSold 119,137 shares on 5/7/2024Ownership: 0.031%Susquehanna Fundamental Investments LLCBought 13,818 shares on 5/7/2024Ownership: 0.026%BNP Paribas Financial MarketsSold 60,861 shares on 5/1/2024Ownership: 0.060%HighMark Wealth Management LLCBought 9,150 shares on 4/29/2024Ownership: 0.031%China Universal Asset Management Co. Ltd.Bought 4,157 shares on 4/29/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions PRTA Stock Analysis - Frequently Asked Questions Should I buy or sell Prothena stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PRTA shares. View PRTA analyst ratings or view top-rated stocks. What is Prothena's stock price target for 2024? 7 Wall Street research analysts have issued 1-year target prices for Prothena's stock. Their PRTA share price targets range from $35.00 to $90.00. On average, they anticipate the company's stock price to reach $68.14 in the next twelve months. This suggests a possible upside of 184.5% from the stock's current price. View analysts price targets for PRTA or view top-rated stocks among Wall Street analysts. How have PRTA shares performed in 2024? Prothena's stock was trading at $36.34 at the beginning of the year. Since then, PRTA stock has decreased by 34.1% and is now trading at $23.95. View the best growth stocks for 2024 here. When is Prothena's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PRTA earnings forecast. How were Prothena's earnings last quarter? Prothena Co. plc (NASDAQ:PRTA) issued its quarterly earnings results on Thursday, February, 15th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by $0.03. The biotechnology company earned $0.32 million during the quarter, compared to analysts' expectations of $2.15 million. Prothena had a negative trailing twelve-month return on equity of 24.84% and a negative net margin of 160.91%. Prothena's revenue for the quarter was down 99.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.12 EPS. What ETF holds Prothena's stock? iShares Neuroscience and Healthcare ETF holds 3,352 shares of PRTA stock, representing 2.00% of its portfolio. What other stocks do shareholders of Prothena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD). Who are Prothena's major shareholders? Prothena's stock is owned by many different retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.23%), BNP Paribas Financial Markets (0.06%), SG Americas Securities LLC (0.03%), HighMark Wealth Management LLC (0.03%), Susquehanna Fundamental Investments LLC (0.03%) and Principal Financial Group Inc. (0.02%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago. View institutional ownership trends. How do I buy shares of Prothena? Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRTA) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersAI “wealth window” is closing June 25thParadigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe asset beating inflation by 4xColonial MetalsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
